Aspartylglucosaminuria

Aspartylglucosaminuria is a condition that causes a progressive decline in mental functioning.

Infants with aspartylglucosaminuria appear healthy at birth, and development is typically normal throughout early childhood. The first sign of this condition, evident around the age of 2 or 3, is usually delayed speech. Mild intellectual disability then becomes apparent, and learning occurs at a slowed pace. Intellectual disability progressively worsens in adolescence. Most people with this disorder lose much of the speech they have learned, and affected adults usually have only a few words in their vocabulary. Adults with aspartylglucosaminuria may develop seizures or problems with movement.

People with this condition may also have bones that become progressively weak and prone to fracture (osteoporosis), an unusually large range of joint movement (hypermobility), and loose skin. Affected individuals tend to have a characteristic facial appearance that includes widely spaced eyes (ocular hypertelorism), small ears, and full lips. The nose is short and broad and the face is usually square-shaped. Children with this condition may be tall for their age, but lack of a growth spurt in puberty typically causes adults to be short. Affected children also tend to have frequent upper respiratory infections. Individuals with aspartylglucosaminuria usually survive into mid-adulthood.

Frequency

Aspartylglucosaminuria is estimated to affect 1 in 18,500 people in Finland. This condition is less common outside of Finland, but the incidence is unknown.

Causes

Mutations in the AGA gene cause aspartylglucosaminuria. The AGA gene provides instructions for producing an enzyme called aspartylglucosaminidase. This enzyme is active in lysosomes, which are structures inside cells that act as recycling centers. Within lysosomes, the enzyme helps break down complexes of sugar molecules (oligosaccharides) attached to certain proteins (glycoproteins).

AGA gene mutations result in the absence or shortage of the aspartylglucosaminidase enzyme in lysosomes, preventing the normal breakdown of glycoproteins. As a result, glycoproteins can build up within the lysosomes. Excess glycoproteins disrupt the normal functions of the cell and can result in destruction of the cell. A buildup of glycoproteins seems to particularly affect nerve cells in the brain; loss of these cells causes many of the signs and symptoms of aspartylglucosaminuria.
Inheritance Pattern

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other Names for This Condition

- AGA deficiency
- aspartylglucosamidase deficiency
- Aspartylglucosaminidase deficiency
- aspartylglycosaminuria
- glycosylasparaginase deficiency

Diagnosis & Management

Genetic Testing Information

- What is genetic testing? https://primer/testing/genetictesting

Research Studies from ClinicalTrials.gov

- ClinicalTrials.gov https://clinicaltrials.gov/ct2/results?cond=%22aspartylglucosaminuria%22

Additional Information & Resources

Health Information from MedlinePlus

- Health Topic: Genetic Brain Disorders https://medlineplus.gov/geneticbraindisorders.html
- Health Topic: Metabolic Disorders https://medlineplus.gov/metabolicdisorders.html

Genetic and Rare Diseases Information Center

- Aspartylglycosaminuria https://rarediseases.info.nih.gov/diseases/5854/aspartylglycosaminuria
Additional NIH Resources

• National Institute of Neurological Disorders and Stroke: Cerebral Atrophy Information Page
  https://www.ninds.nih.gov/Disorders/All-Disorders/Cerebral-atrophy-Information-Page

Educational Resources

• Centers for Disease Control and Prevention: Intellectual Disability

• KidsHealth: Delayed Speech or Language Development

• MalaCards: aspartylglucosaminuria
  https://www.malacards.org/card/aspartylglucosaminuria

• Orphanet: Aspartylglucosaminuria
  https://www.orpha.net/consor/cgi-bin/OC_Exp.php?Lng=EN&Expert=93

• The MPS Society (UK): Guide to Understanding Aspartylglucosaminuria
  https://docs.wixstatic.com/ugd/2a10d4_96598dc7fe8d4937a1c5267f10147f56.pdf

Patient Support and Advocacy Resources

• Family Caregiver Alliance
  https://www.caregiver.org/

• ISMRD: The International Advocate for Glycoprotein Storage Diseases
  https://www.ismrd.org/

• Metabolic Support UK
  https://www.metabolicsupportuk.org/

• National Organization for Rare Disorders (NORD)
  https://rarediseases.org/rare-diseases/aspartylglycosaminuria/

• The MPS Society (UK)
  https://www.mpssociety.org.uk/

Scientific Articles on PubMed

• PubMed
  https://www.ncbi.nlm.nih.gov/pubmed?term=%28aspartylglucosaminuria%5BTIAB%5D%29+AND+english%5BLa%5D+AND+human%5Bmh%5D+AND+%22last+3600+days%22%5BDp%5D

Catalog of Genes and Diseases from OMIM

• ASPARTYLGLUCOSAMINURIA
  http://omim.org/entry/208400
Sources for This Summary

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10571008

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15127757

  Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11309371

Reprinted from Genetics Home Reference: 

Reviewed: December 2008
Published: August 17, 2020

Lister Hill National Center for Biomedical Communications
U.S. National Library of Medicine
National Institutes of Health
Department of Health & Human Services